{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:56:09Z","timestamp":1791233769666,"version":"4.1.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI170205"],"award-info":[{"award-number":["R01 AI170205"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.celrep.2026.117558","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T21:46:45Z","timestamp":1781905605000},"page":"117558","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive mapping of the virus and host factors that guide the paths of HIV-1 escape from a therapeutic"],"prefix":"10.1016","volume":"45","author":[{"given":"Aaron N.","family":"Gillman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassian M.","family":"Birler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohith Rao","family":"Vujjini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Fili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel A.","family":"McCarthy-Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline M.","family":"Broghammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret J.","family":"Gartland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manyu","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Helverson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant G.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6071-5089","authenticated-orcid":false,"given":"Hillel","family":"Haim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.celrep.2026.117558_bib1","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1128\/jvi.69.8.5087-5094.1995","article-title":"Lower in-Vivo Mutation-Rate of Human-Immunodeficiency-Virus Type-1 Than That Predicted from the Fidelity of Purified Reverse-Transcriptase","volume":"69","author":"Mansky","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2026.117558_bib2","doi-asserted-by":"crossref","first-page":"9733","DOI":"10.1128\/JVI.00694-10","article-title":"Viral mutation rates","volume":"84","author":"Sanju\u00e1n","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2026.117558_bib3","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1021\/bi00119a002","article-title":"Fidelity of HIV-1 reverse transcriptase copying RNA in vitro","volume":"31","author":"Ji","year":"1992","journal-title":"Biochemistry"},{"key":"10.1016\/j.celrep.2026.117558_bib4","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3390\/v12030297","article-title":"The Determination of HIV-1 RT Mutation Rate, Its Possible Allosteric Effects, and Its Implications on Drug Resistance","volume":"12","author":"Yeo","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.celrep.2026.117558_bib5","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.3390\/v3112255","article-title":"Viral determinants of HIV-1 macrophage tropism","volume":"3","author":"Duncan","year":"2011","journal-title":"Viruses"},{"key":"10.1016\/j.celrep.2026.117558_bib6","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/01.qai.0000152835.17747.47","article-title":"R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy","volume":"38","author":"Delobel","year":"2005","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.celrep.2026.117558_bib7","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00406-22","article-title":"Commonly Elicited Antibodies against the Base of the HIV-1 Env Trimer Guide the Population-Level Evolution of a Structure-Regulating Region in gp41","volume":"96","author":"Rojas Ch\u00e1vez","year":"2022","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2026.117558_bib8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3390\/v11040311","article-title":"HIV-1 Envelope Glycoprotein at the Interface of Host Restriction and Virus Evasion","volume":"11","author":"Beitari","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.celrep.2026.117558_bib9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2013.01.007","article-title":"Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments","volume":"98","author":"Men\u00e9ndez-Arias","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.celrep.2026.117558_bib10","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/jac\/dki038","article-title":"The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance","volume":"55","author":"No\u00eb","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.celrep.2026.117558_bib11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.antiviral.2011.10.010","article-title":"Compensatory mutations rescue the virus replicative capacity of VIRIP-resistant HIV-1","volume":"92","author":"Gonz\u00e1lez-Ortega","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.celrep.2026.117558_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad5752","article-title":"Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection","volume":"7","author":"Lynch","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.celrep.2026.117558_bib13","doi-asserted-by":"crossref","first-page":"9040","DOI":"10.1073\/pnas.1820333116","article-title":"Mutations in the HIV-1 envelope glycoprotein can broadly rescue blocks at multiple steps in the virus replication cycle","volume":"116","author":"Van Duyne","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2026.117558_bib14","doi-asserted-by":"crossref","first-page":"7589","DOI":"10.1128\/JVI.00302-14","article-title":"Mutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replication","volume":"88","author":"Abram","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2026.117558_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2024.168815","article-title":"HIV-1 Reverse Transcriptase Error Rates and Transcriptional Thresholds Based on Single-strand Consensus Sequencing of Target RNA Derived From In Vitro-transcription and HIV-infected Cells","volume":"436","author":"Mart\u00ednez del R\u00edo","year":"2024","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.celrep.2026.117558_bib16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12977-015-0180-6","article-title":"HIV-1 and HIV-2 exhibit similar mutation frequencies and spectra in the absence of G-to-A hypermutation","volume":"12","author":"Rawson","year":"2015","journal-title":"Retrovirology"},{"key":"10.1016\/j.celrep.2026.117558_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2001549","article-title":"Accurate predictions of population-level changes in sequence and structural properties of HIV-1 Env using a volatility-controlled diffusion model","volume":"15","author":"DeLeon","year":"2017","journal-title":"PLoS Biol."},{"key":"10.1016\/j.celrep.2026.117558_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00126-20","article-title":"Key Positions of HIV-1 Env and Signatures of Vaccine Efficacy Show Gradual Reduction of Population Founder Effects at the Clade and Regional Levels","volume":"11","author":"Han","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.celrep.2026.117558_bib19","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s40265-020-01386-w","article-title":"Fostemsavir: First Approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.celrep.2026.117558_bib20","doi-asserted-by":"crossref","first-page":"6308","DOI":"10.1021\/acs.jmedchem.8b00759","article-title":"Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir","volume":"61","author":"Wang","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.celrep.2026.117558_bib21","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1007\/s40121-023-00870-6","article-title":"Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1","volume":"12","author":"Aberg","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.celrep.2026.117558_bib22","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1902493","article-title":"Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection","volume":"382","author":"Kozal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.celrep.2026.117558_bib23","doi-asserted-by":"crossref","first-page":"e740","DOI":"10.1016\/S2352-3018(20)30240-X","article-title":"Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study","volume":"7","author":"Lataillade","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.celrep.2026.117558_bib24","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/infdis\/jiad503","article-title":"Plasma Human Immunodeficiency Virus 1 Soluble Glycoprotein 120 Association With Correlates of Immune Dysfunction and Inflammation in Antiretroviral Therapy-Treated Individuals With Undetectable Viremia","volume":"229","author":"Benlarbi","year":"2024","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.celrep.2026.117558_bib25","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.chembiol.2023.03.003","article-title":"Temsavir blocks the immunomodulatory activities of HIV-1 soluble gp120","volume":"30","author":"Richard","year":"2023","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.celrep.2026.117558_bib26","doi-asserted-by":"crossref","first-page":"ofae469","DOI":"10.1093\/ofid\/ofae469","article-title":"Inflammatory Biomarker Reduction With Fostemsavir Over 96 Weeks in Heavily Treatment-Experienced Adults With Multidrug-Resistant HIV-1 in the BRIGHTE Study","volume":"11","author":"Clark","year":"2024","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.celrep.2026.117558_bib27","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01751-21","article-title":"Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1","volume":"66","author":"Gartland","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.celrep.2026.117558_bib28","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/jps.23476","article-title":"Compartmental absorption modeling and site of absorption studies to determine feasibility of an extended-release formulation of an HIV-1 attachment inhibitor phosphate ester prodrug","volume":"102","author":"Brown","year":"2013","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.celrep.2026.117558_bib29","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12879-024-09122-5","article-title":"Mechanism of action, resistance, interaction, pharmacokinetics, pharmacodynamics, and safety of fostemsavir","volume":"24","author":"Heidary","year":"2024","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.celrep.2026.117558_bib30","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3390\/v13050843","article-title":"Small Molecule HIV-1 Attachment Inhibitors: Discovery, Mode of Action and Structural Basis of Inhibition","volume":"13","author":"Lai","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.celrep.2026.117558_bib31","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/prot.24726","article-title":"Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action","volume":"83","author":"Langley","year":"2015","journal-title":"Proteins."},{"key":"10.1016\/j.celrep.2026.117558_bib32","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/QAI.0000000000001602","article-title":"Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir","volume":"77","author":"Lataillade","year":"2018","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.celrep.2026.117558_bib33","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/jac\/dkaa474","article-title":"Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense(R) Entry assay","volume":"76","author":"Gartland","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.celrep.2026.117558_bib34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/QAI.0b013e31829726f3","article-title":"Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068","volume":"64","author":"Ray","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.celrep.2026.117558_bib35","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/jac\/dkt412","article-title":"Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068","volume":"69","author":"Zhou","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.celrep.2026.117558_bib36","doi-asserted-by":"crossref","first-page":"6710","DOI":"10.1038\/s41467-023-42500-2","article-title":"Structure-function analyses reveal key molecular determinants of HIV-1 CRF01_AE resistance to the entry inhibitor temsavir","volume":"14","author":"Pr\u00e9vost","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2026.117558_bib37","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1093\/jac\/dkab257","article-title":"Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV Sequence Database","volume":"76","author":"Gartland","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.celrep.2026.117558_bib38","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/nchembio.2460","article-title":"Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529","volume":"13","author":"Pancera","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.celrep.2026.117558_bib39","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01251-23","article-title":"Fostemsavir resistance-associated polymorphisms in HIV-1 subtype C in a large cohort of treatment-naive and treatment-experienced individuals in Botswana","volume":"11","author":"Zuze","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.celrep.2026.117558_bib40","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1128\/AAC.00759-10","article-title":"Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects","volume":"55","author":"Hanna","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.celrep.2026.117558_bib41","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1093\/infdis\/jis432","article-title":"Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects","volume":"206","author":"Nettles","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.celrep.2026.117558_bib42","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00280-20","article-title":"The HIV-1 Env gp120 Inner Domain Shapes the Phe43 Cavity and the CD4 Binding Site","volume":"11","author":"Pr\u00e9vost","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.celrep.2026.117558_bib43","first-page":"102","article-title":"Numbering positions in HIV relative to HXBc2","volume":"3","author":"Korber","year":"1998","journal-title":"Human retroviruses and AIDS"},{"key":"10.1016\/j.celrep.2026.117558_bib44","series-title":"Kdd'16: Proceedings of the 22nd Acm Sigkdd International Conference on Knowledge Discovery and Data Mining","first-page":"785","article-title":"XGBoost: A Scalable Tree Boosting System","author":"Chen","year":"2016"},{"key":"10.1016\/j.celrep.2026.117558_bib45","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s42256-019-0138-9","article-title":"From Local Explanations to Global Understanding with Explainable AI for Trees","volume":"2","author":"Lundberg","year":"2020","journal-title":"Nat. Mach. Intell."},{"key":"10.1016\/j.celrep.2026.117558_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.105957","article-title":"Characterization of clinical envelopes with lack of sensitivity to the HIV-1 inhibitors temsavir and ibalizumab","volume":"228","author":"Gartland","year":"2024","journal-title":"Antivir. Res."},{"key":"10.1016\/j.celrep.2026.117558_bib47","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.virol.2010.03.033","article-title":"Increased sensitivity of HIV variants selected by attachment inhibitors to broadly neutralizing antibodies","volume":"402","author":"Zhou","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.celrep.2026.117558_bib48","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1128\/JVI.72.3.2509-2515.1998","article-title":"Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4","volume":"72","author":"Cho","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2026.117558_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002101","article-title":"Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity","volume":"7","author":"Haim","year":"2011","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.celrep.2026.117558_bib50","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1128\/JVI.02108-09","article-title":"Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies","volume":"84","author":"Seaman","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2026.117558_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050859","article-title":"Quantification of reverse transcriptase activity by real-time PCR as a fast and accurate method for titration of HIV, lenti- and retroviral vectors","volume":"7","author":"Vermeire","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.celrep.2026.117558_bib52","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.34420","article-title":"Mapping mutational effects along the evolutionary landscape of HIV envelope","volume":"7","author":"Haddox","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.celrep.2026.117558_bib53","doi-asserted-by":"crossref","first-page":"E69","DOI":"10.1073\/pnas.1217609110","article-title":"Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding","volume":"110","author":"Guan","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2026.117558_bib54","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01405-21","article-title":"Across Functional Boundaries: Making Nonneutralizing Antibodies To Neutralize HIV-1 and Mediate Fc-Mediated Effector Killing of Infected Cells","volume":"12","author":"Richard","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.celrep.2026.117558_bib55","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/COH.0b013e328363d486","article-title":"New paradigms for functional HIV-specific nonneutralizing antibodies","volume":"8","author":"Forthal","year":"2013","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.celrep.2026.117558_bib56","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.3389\/fimmu.2017.01590","article-title":"Non-Neutralizing Antibodies Directed against HIV and Their Functions","volume":"8","author":"Mayr","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.celrep.2026.117558_bib57","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.cell.2017.06.048","article-title":"Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo","volume":"170","author":"Horwitz","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2026.117558_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010046","article-title":"ADCC-mediating non-neutralizing antibodies can exert immune pressure in early HIV-1 infection","volume":"17","author":"Mielke","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.celrep.2026.117558_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005042","article-title":"Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques","volume":"11","author":"Santra","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.celrep.2026.117558_bib60","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1128\/JVI.02765-12","article-title":"Proteolytic processing of the human immunodeficiency virus envelope glycoprotein precursor decreases conformational flexibility","volume":"87","author":"Haim","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2026.117558_bib61","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00174-17","article-title":"Induction of a Tier-1-Like Phenotype in Diverse Tier-2 Isolates by Agents That Guide HIV-1 Env to Perturbation-Sensitive, Nonnative States","volume":"91","author":"Johnson","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2026.117558_bib62","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.immuni.2017.03.017","article-title":"A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic beta-Hairpin Structure","volume":"46","author":"Lee","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.celrep.2026.117558_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.101819","article-title":"Antigenic analysis of the HIV-1 envelope trimer implies small differences between structural states 1 and 2","volume":"298","author":"Cale","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.celrep.2026.117558_bib64","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1126\/science.1254426","article-title":"Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions","volume":"346","author":"Munro","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.celrep.2026.117558_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021339","article-title":"Functional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 (HIV-1)","volume":"6","author":"Agrawal","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.celrep.2026.117558_bib66","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01216-17","article-title":"Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex","volume":"91","author":"Gift","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2026.117558_bib67","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1128\/JVI.02868-14","article-title":"The HIV-1 gp120 CD4-bound conformation is preferentially targeted by antibody-dependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individuals","volume":"89","author":"Veillette","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2026.117558_bib68","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.ebiom.2015.09.001","article-title":"HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans","volume":"2","author":"Williams","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.celrep.2026.117558_bib69","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1128\/JVI.75.5.2041-2050.2001","article-title":"Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants","volume":"75","author":"Kolchinsky","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2026.117558_bib70","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1074\/jbc.RA119.009481","article-title":"The lipid membrane of HIV-1 stabilizes the viral envelope glycoproteins and modulates their sensitivity to antibody neutralization","volume":"295","author":"Salimi","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.celrep.2026.117558_bib71","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00592-23","article-title":"Alterations in gp120 glycans or the gp41 fusion peptide-proximal region modulate the stability of the human immunodeficiency virus (HIV-1) envelope glycoprotein pretriggered conformation","volume":"97","author":"Zhang","year":"2023","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2026.117558_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000360","article-title":"Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state","volume":"5","author":"Haim","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.celrep.2026.117558_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008177","article-title":"Deep sequence analysis of HIV adaptation following vertical transmission reveals the impact of immune pressure on the evolution of HIV","volume":"15","author":"Currenti","year":"2019","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.celrep.2026.117558_bib74","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/eji.201747172","article-title":"Mechanisms of CD8(+) T cell-mediated suppression of HIV\/SIV replication","volume":"48","author":"McBrien","year":"2018","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.celrep.2026.117558_bib75","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1128\/jvi.69.7.4413-4422.1995","article-title":"Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates","volume":"69","author":"Sullivan","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2026.117558_bib76","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2222073120","article-title":"Indoline CD4-mimetic compounds mediate potent and broad HIV-1 inhibition and sensitization to antibody-dependent cellular cytotoxicity","volume":"120","author":"Fritschi","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2026.117558_bib77","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01638-22","article-title":"Characterization of a Novel CD4 Mimetic Compound YIR-821 against HIV-1 Clinical Isolates","volume":"97","author":"Matsumoto","year":"2023","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2026.117558_bib78","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1093\/nar\/gkg575","article-title":"Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes","volume":"31","author":"Beerenwinkel","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.celrep.2026.117558_bib79","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1128\/JCM.42.6.2711-2717.2004","article-title":"Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System for sequence-based analysis of diverse human immunodeficiency virus type 1 strains","volume":"42","author":"Eshleman","year":"2004","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.celrep.2026.117558_bib80","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation","volume":"42","author":"Liu","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.celrep.2026.117558_bib81","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1128\/JCM.01204-10","article-title":"Performance of genotypic algorithms for predicting HIV-1 tropism measured against the enhanced-sensitivity Trofile coreceptor tropism assay","volume":"48","author":"S\u00e1nchez","year":"2010","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.celrep.2026.117558_bib82","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-50635-w","article-title":"Accurate Prediction for Antibody Resistance of Clinical HIV-1 Isolates","volume":"9","author":"Rawi","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.celrep.2026.117558_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1006952","article-title":"Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features","volume":"15","author":"Magaret","year":"2019","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.celrep.2026.117558_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107595","article-title":"Application of the SLAPNAP statistical learning tool to broadly neutralizing antibody HIV prevention research","volume":"26","author":"Williamson","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.celrep.2026.117558_bib85","unstructured":"Kantor, R. (2024). Overview of HIV-1 drug resistance testing assays. https:\/\/www.uptodate.com\/contents\/overview-of-hiv-1-drug-resistance-testing-assays#H1277302675."},{"key":"10.1016\/j.celrep.2026.117558_bib86","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1086\/596736","article-title":"Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes","volume":"199","author":"Simen","year":"2009","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.celrep.2026.117558_bib87","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.03134-20","article-title":"Mechanistic Analysis of the Broad Antiretroviral Resistance Conferred by HIV-1 Envelope Glycoprotein Mutations","volume":"12","author":"Hikichi","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.celrep.2026.117558_bib88","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/molbev\/mst010","article-title":"MAFFT multiple sequence alignment software version 7: improvements in performance and usability","volume":"30","author":"Katoh","year":"2013","journal-title":"Mol. Biol. Evol."},{"key":"10.1016\/j.celrep.2026.117558_bib89","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1089\/aid.1995.11.1413","article-title":"A computer program designed to screen rapidly for HIV type 1 intersubtype recombinant sequences","volume":"11","author":"Siepel","year":"1995","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.celrep.2026.117558_bib90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009490","article-title":"FastTree 2--approximately maximum-likelihood trees for large alignments","volume":"5","author":"Price","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.celrep.2026.117558_bib91","doi-asserted-by":"crossref","first-page":"W83","DOI":"10.1093\/nar\/gkae410","article-title":"The Galaxy platform for accessible, reproducible, and collaborative data analyses: 2024 update","volume":"52","author":"Galaxy","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.celrep.2026.117558_bib92","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/molbev\/msz197","article-title":"HyPhy 2.5-A Customizable Platform for Evolutionary Hypothesis Testing Using Phylogenies","volume":"37","author":"Kosakovsky Pond","year":"2020","journal-title":"Mol. Biol. Evol."},{"key":"10.1016\/j.celrep.2026.117558_bib93","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1128\/jvi.64.5.2416-2420.1990","article-title":"Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants","volume":"64","author":"Helseth","year":"1990","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2026.117558_bib94","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.chom.2013.10.006","article-title":"Modeling virus- and antibody-specific factors to predict human immunodeficiency virus neutralization efficiency","volume":"14","author":"Haim","year":"2013","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.celrep.2026.117558_bib95","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1128\/jvi.70.2.1100-1108.1996","article-title":"Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1","volume":"70","author":"Trkola","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2026.117558_bib96","first-page":"52","article-title":"HIV sequence databases","volume":"5","author":"Kuiken","year":"2003","journal-title":"AIDS Rev."},{"key":"10.1016\/j.celrep.2026.117558_bib97","first-page":"2825","article-title":"Scikit-learn: Machine Learning in Python","volume":"12","author":"Pedregosa","year":"2011","journal-title":"J. Mach. Learn. Res."},{"key":"10.1016\/j.celrep.2026.117558_bib98","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/ncomms1325","article-title":"A novel methodology for large-scale phylogeny partition","volume":"2","author":"Prosperi","year":"2011","journal-title":"Nat. Commun."}],"container-title":["Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124726006364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124726006364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:26:45Z","timestamp":1791232005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124726006364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":98,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2211124726006364"],"URL":"https:\/\/doi.org\/10.1016\/j.celrep.2026.117558","relation":{},"ISSN":["2211-1247"],"issn-type":[{"value":"2211-1247","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive mapping of the virus and host factors that guide the paths of HIV-1 escape from a therapeutic","name":"articletitle","label":"Article Title"},{"value":"Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.celrep.2026.117558","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117558"}}